Rheumatoid arthritis (RA) is a chronic autoimmune condition of the connective tissue in synovial joints characterized by inflammation that can lead to impaired movement and disability. Current clinical guidelines recommend a combination of small-molecule disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate as a first-line therapy, however their ability to suppress disease progression and joint destruction is limited for a substantial proportion of patients. DMARDs can slow the progression of rheumatoid arthritis and save the joints and other tissues from permanent damage. Common DMARDs include methotrexate (Trexall, Otrexup, Rasuvo), leflunomide (Arava), hydroxychloroquine (Plaquenil) and sulfasalazine (Azulfidine). Biological drugs such as inhibitors of tumor necrosis factor (TNF) blocks the activity of key inflammatory mediators that give rise to the main characteristics of RA. These include infliximab (Remicade), adalimumab (Humira), etanercept (Enbrel), golimumab (Simponi) and certolizumab pegol (Cimzia). Several other biological response modifiers such as checkpoint inhibitor, cytotoxic T lymphocyte-associated protein 4 (CTLA4) inhibits the production of inflammatory cytokines such as TNF, interferon-γ and interleukin-2 (IL-2). These include abatacept (Orencia), Rituximab (MabThera), and Tocilizumab (Actemra/RoActemra). Janus Kinase (JAK) inhibitors such as Tofacitinib (Xeljanz), Filgotinib and baricitinib are recently approved by the US FDA, while a number of promising RA therapies are in development.
The global rheumatoid arthritis drugs market segmentation is based on drug class – disease-modifying anti-rheumatic drugs (DMARDs), tumor necrosis factor (TNF) inhibitors, Janus kinase (JAK) inhibitors, and other biologics.
The global rheumatoid arthritis drugs market research report provides market size (Revenue USD Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global rheumatoid arthritis drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global rheumatoid arthritis drugs market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
Major players operating in the global rheumatoid arthritis drugs market and profiled in this report include AbbVie, Ablynx, Alder Biopharmaceuticals, Amgen, Bristol-Myers Squibb, Centocor, Daiichi Sankyo, Eli Lilly, Galapagos NV, Genentech (Roche), Gilead, GlaxoSmithKline, Incyte Corp., Janssen Biotech, Johnson & Johnson, MedImmune, Merck & Co., Pfizer, Regeneron, Sanofi, and UCB.